Merck & Co., Inc. MRK
148.78
0.80
0.54%
as of 25 Sep
- Market cap
- $365.4B
- P/E
- 119×
Follow MRK
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Merck & Co., Inc. (MRK) Return on equity
Merck & Co., Inc.'s return on equity over the twelve months to 30 June 2026 was 6.97%, down 29.9 percentage points from fiscal 2025 (36.9%). Over the past ten years it has ranged from 0.87% (fiscal 2023) to 41.0% (fiscal 2021); the current reading is higher than 73% of that period. That is in line with the Drug Manufacturers General industry median of 6.97% and above the Healthcare sector median of −32.0%.
Return on equity, annual
Annual
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 36.9% | (3.89) |
| FY2024 | 40.8% | 39.88 |
| FY2023 | 0.87% | (33.57) |
| FY2022 | 34.4% | (6.56) |
| FY2021 | 41.0% | 13.50 |
| FY2020 | 27.5% | (9.73) |
| FY2019 | 37.2% | 16.99 |
| FY2018 | 20.2% | 13.85 |
| FY2017 | 6.39% | (2.83) |
| FY2016 | 9.22% | (0.28) |
Against its own ten years
Low 0.87%
High 41.0%
Ten-year median
27.5%
Current reading's percentile
73
Return on equity against peers
| Company | Return on equity |
|---|---|
| AMGN Amgen Inc. compare | 91.5% |
| NVO Novo Nordisk A/S compare | 60.8% |
| NVS Novartis AG compare | 30.4% |
| JNJ Johnson & Johnson compare | 25.7% |
| AZN AstraZeneca PLC compare | 22.0% |
| MRK Merck & Co., Inc. | 6.97% |
| PFE Pfizer Inc. compare | 4.97% |
| GILD Gilead Sciences, Inc. compare | −20.7% |
| ABBV AbbVie Inc. compare | −208.1% |
| Drug Manufacturers General industry median | 6.97% |
| Healthcare sector median | −32.0% |
| Market median | 1.76% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on MRK
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement